Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott McComb

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Fluids and Barriers of the CNS|June 1, 2022
Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapiesJez Huang, Ying Betty Li, Claudie Charlebois, et al.
Journal of Clinical Medicine|July 27, 2022
Maternal Immune Cell and Cytokine Profiles to Predict Cardiovascular Risk Six Months after PreeclampsiaMalia S Q Murphy, Samantha J Benton, Brian Cox, et al.
Blood Advances|October 7, 2020
TNFR2 is required for RIP1-dependent cell death in human leukemiaJúlia Aguadé-Gorgorió, Scott McComb, Cornelia Eckert, et al.
Molecular Therapy. Methods & Clinical Development|February 22, 2020
A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat CellsDarin Bloemberg, Tina Nguyen, Susanne MacLean, et al.
Transfusion Medicine Reviews|April 25, 2025
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-AnalysisManoj M Lalu, Samuel Igweokpala, Natasha Kekre, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Communications|August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Molecular Therapy. Oncology|April 10, 2024
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22Scott McComb, Mehdi Arbabi-Ghahroudi, Kevin A Hay, et al.
Antibody Therapeutics|September 24, 2025
Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cellsScott McComb, Bianca Dupont, Alex Shepherd, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Fluids and Barriers of the CNS|June 1, 2022
Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapiesJez Huang, Ying Betty Li, Claudie Charlebois, et al.
Journal of Clinical Medicine|July 27, 2022
Maternal Immune Cell and Cytokine Profiles to Predict Cardiovascular Risk Six Months after PreeclampsiaMalia S Q Murphy, Samantha J Benton, Brian Cox, et al.
Blood Advances|October 7, 2020
TNFR2 is required for RIP1-dependent cell death in human leukemiaJúlia Aguadé-Gorgorió, Scott McComb, Cornelia Eckert, et al.
Molecular Therapy. Methods & Clinical Development|February 22, 2020
A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat CellsDarin Bloemberg, Tina Nguyen, Susanne MacLean, et al.
Transfusion Medicine Reviews|April 25, 2025
Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-AnalysisManoj M Lalu, Samuel Igweokpala, Natasha Kekre, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Communications|August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Molecular Therapy. Oncology|April 10, 2024
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22Scott McComb, Mehdi Arbabi-Ghahroudi, Kevin A Hay, et al.
Antibody Therapeutics|September 24, 2025
Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cellsScott McComb, Bianca Dupont, Alex Shepherd, et al.
Pageof 4